01—Abstract
Summary
Summary of the 8-K filed May 8, 2024. Cited figures are marked; the original filing is the authoritative source.
BeiGene, Ltd. (NASDAQ: BGNE), which has since been renamed BeOne Medicines, reported first quarter 2024 total revenue of $752 milliona, up 68% year over year.
Product revenue rose 82% to $747 millionb, led by BRUKINSA, with U.S. sales of $351 million (up 153%) and European sales of $67 million (up 243%). Gross margin on product revenue improved to 83% from 80%, and SG&A fell to 57% of product sales from 80%. Collaboration revenue dropped 87% to $5 million, reflecting the prior-year period's higher collaboration income.
GAAP operating loss narrowed 30% to $261 millionc, and adjusted operating loss narrowed 47% to $147 million, which management attributes to operating leverage from revenue growth and expense discipline. GAAP net loss improved to $251 million from $348 million, or $(0.19) per share and $(2.41) per ADS. Operating cash burn fell sharply to $309 million from $564 million.
Cash, cash equivalents, restricted cash and short-term investments declined to $2.81 billiond from $3.19 billion at year-end 2023, while debt rose to about $1.03 billion from $886 million, so liquidity and the path to sustained profitability remain key watch items. Pipeline and regulatory news was mixed. Tislelizumab sales grew 26% to $145 million, and the company received FDA approval for second-line esophageal cancer, but management warned that the July 2024 PDUFA date for first-line ESCC may be deferred due to possible delays in clinical site inspection scheduling.
The company also reported FDA fast track designation for sonrotoclax in relapsed or refractory mantle cell lymphoma and a USPTO decision to institute post-grant review of a Pharmacyclics patent. Note that the 8-K portions furnished under Item 2.02 are not deemed filed for Exchange Act Section 18 purposes.
02—Key points
Key Highlights
- Total revenue of $752 million rose 68% year over year, and product revenue of $747 million rose 82%, driven by BRUKINSA and tislelizumab.
- BRUKINSA revenue reached $489 million, with U.S. sales of $351 million (up 153%) and European sales of $67 million (up 243%); the company says its label is now the broadest in the BTK inhibitor class after a fifth FDA approval.
- Operating leverage improved sharply: GAAP operating loss fell 30% to $261 million, adjusted operating loss fell 47% to $147 million, and SG&A dropped to 57% of product sales from 80%.
- Gross margin on product revenue expanded to 83% from 80%, reflecting a higher mix of BRUKINSA.
- Net loss narrowed to $251 million from $348 million, or $(0.19) per share, and operating cash burn fell to $309 million from $564 million.
- Cash and short-term investments declined to $2.81 billion from $3.19 billion, and debt increased to about $1.03 billion, leaving liquidity as a key consideration.
- Regulatory and pipeline risk: the July 2024 PDUFA date for first-line ESCC tislelizumab may be deferred due to potential delays in clinical site inspection scheduling, while sonrotoclax received FDA fast track designation in relapsed or refractory mantle cell lymphoma.
03—Questions
Frequently Asked Questions
How strong was the revenue growth, and what drove it?
Total revenue rose 68% to $752 million, and product revenue rose 82% to $747 million. Growth was driven mainly by BRUKINSA, which generated $489 million in sales, with the U.S. and Europe growing 153% and 243% respectively. Tislelizumab sales grew 26% to $145 million. Collaboration revenue fell 87% to $5 million, so the top-line growth came entirely from product sales.
Is the company approaching profitability?
The company is narrowing losses but is not yet profitable. GAAP operating loss was $261 million and net loss was $251 million for the quarter. Adjusted operating loss, which excludes share-based compensation and depreciation, was $147 million. Management points to strong operating leverage and expense discipline as progress toward sustainable profitability, but the filing does not provide a profitability timeline.
How is the company's cash position and balance sheet?
Cash, cash equivalents, restricted cash and short-term investments declined to $2.81 billion from $3.19 billion at December 31, 2023, and operating cash use fell to $309 million from $564 million. Debt rose to about $1.03 billion from $886 million, and total equity declined to $3.36 billion. Investors should monitor how long current liquidity lasts as the company funds its pipeline and commercial expansion.
What regulatory risks should investors watch?
The company said the pending FDA decision on first-line unresectable or metastatic ESCC for tislelizumab, with a target PDUFA date of July 2024, may be deferred because of potential delays in scheduling clinical site inspections. The company also reported that a BLA for first-line gastric or gastroesophageal junction cancer had been accepted by the FDA. Investors should monitor FDA timing and inspection-related delays.
04—Continue